The German pharmaceutical company DR.KADE acquired six phyto-pharmaceutical products from Hexal AG, by this move strengthening one of its core competencies, the gynecology sector. Part of of the acquired portfolio are the well-known products Femikliman® for treatment of menopausal symptoms and Silicur® for protection of the liver. The business with the acquired phyto-pharmaceutical products shall in the mid-term provide for 10 percent of DR.KADE’s total revenues in the OTC sector.
NOVACOS advised DR.KADE on the acquisition with the following team: Christian Hübner (Lead, Partner, M&A/Life Sciences) and Maria Heil (Partner, M&A/Life Sciences).
This is our press release (in German language): Pressemitteilung NOVACOS 16Jan2017.
The news coverage by Juve is accessible via the following link.